These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16412255)

  • 21. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
    Bergeson JG; Worley K; Louder A; Ward M; Graham J
    J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The status of glycemic control: A cross-sectional study of outpatients with type 2 diabetes mellitus across primary, secondary, and tertiary hospitals in the Jiangsu province of China.
    Bi Y; Zhu D; Cheng J; Zhu Y; Xu N; Cui S; Li W; Cheng X; Wang F; Hu Y; Shen S; Weng J
    Clin Ther; 2010 May; 32(5):973-83. PubMed ID: 20685506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK.
    Bain SC; Bekker Hansen B; Hunt B; Chubb B; Valentine WJ
    J Med Econ; 2020 Jan; 23(1):98-105. PubMed ID: 31311364
    [No Abstract]   [Full Text] [Related]  

  • 24. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of a program to improve diabetes care through intensified care management activities and diabetes medication copayment reduction.
    Kogut SJ; Johnson S; Higgins T; Quilliam B
    J Manag Care Pharm; 2012 May; 18(4):297-310. PubMed ID: 22548690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Defining the role of medication adherence in poor glycemic control among a general adult population with diabetes.
    Feldman BS; Cohen-Stavi CJ; Leibowitz M; Hoshen MB; Singer SR; Bitterman H; Lieberman N; Balicer RD
    PLoS One; 2014; 9(9):e108145. PubMed ID: 25259843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential short-term economic benefits of improved glycemic control: a managed care perspective.
    Menzin J; Langley-Hawthorne C; Friedman M; Boulanger L; Cavanaugh R
    Diabetes Care; 2001 Jan; 24(1):51-5. PubMed ID: 11194241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of poor glycemic control among type 2 diabetes mellitus patients treated with antidiabetic medications: A cross-sectional study in China.
    Wang J; Li J; Wen C; Liu Y; Ma H
    Medicine (Baltimore); 2021 Oct; 100(43):e27677. PubMed ID: 34713865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persistence with Basal-Bolus Insulin Therapy in Patients with Type 2 Diabetes Mellitus and Effect on Clinical and Economic Outcomes: A Retrospective Claims Database Study.
    Edelman SV; Ermakova A; Xiong Y; Sieradzan R; Taylor SD
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1420-1431. PubMed ID: 31550190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycemic control among patients with type 2 diabetes who initiate basal insulin: a retrospective cohort study.
    Curtis B; Lage MJ
    J Med Econ; 2014 Jan; 17(1):21-31. PubMed ID: 24195723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glycemic and Cost Outcomes among Hispanic/Latino People with Type 2 Diabetes in the USA Initiating Dulaglutide versus Basal Insulin: a Real-World Study.
    Hoog M; Maldonado JM; Wangia-Dixon R; Halpern R; Buysman E; Gremel GW; Huang A; Konig M
    Diabetes Ther; 2024 Apr; 15(4):855-867. PubMed ID: 38427164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GOAL study: clinical and non-clinical predictive factors for achieving glycemic control in people with type 2 diabetes in real clinical practice.
    Al Mansari A; Obeid Y; Islam N; Fariduddin M; Hassoun A; Djaballah K; Malek M; Dicker D; Chaudhury T
    BMJ Open Diabetes Res Care; 2018; 6(1):e000519. PubMed ID: 30023075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of Add-on Treatment to Metformin Monotherapy for Patients with Type 2 Diabetes and Suboptimal Glycemic Control: A U.S. Database Study.
    Yu S; Schwab P; Bian B; Radican L; Tunceli K
    J Manag Care Spec Pharm; 2016 Mar; 22(3):272-80. PubMed ID: 27003557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy.
    Vinik A
    Clin Ther; 2007; 29 Spec No():1236-53. PubMed ID: 18046925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resource use and costs in patients with poorly controlled type 2 diabetes mellitus and obesity in routine clinical practice in Spain.
    Díaz-Cerezo S; Romera I; Sicras-Mainar A; López-Simarro F; Dilla T; Artime E; Reviriego J
    Curr Med Res Opin; 2020 Sep; 36(9):1449-1456. PubMed ID: 32643441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M; Peng X; Geremakis C; Bae J
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease.
    Gandra SR; Lawrence LW; Parasuraman BM; Darin RM; Sherman JJ; Wall JL
    J Manag Care Pharm; 2006 Sep; 12(7):546-54. PubMed ID: 16981800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes.
    Shetty S; Secnik K; Oglesby AK
    J Manag Care Pharm; 2005 Sep; 11(7):559-64. PubMed ID: 16137213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine.
    Misurski D; Lage MJ; Fabunmi R; Boye KS
    Appl Health Econ Health Policy; 2009; 7(4):245-54. PubMed ID: 19905038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes.
    Baxter M; Morimoto Y; Tamiwa M; Hattori M; Peng XV; Lubwama R; Maegawa H
    Diabetes Ther; 2020 Jul; 11(7):1481-1496. PubMed ID: 32445125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.